ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,638 | -10.6% | 167 | -14.8% | 0.00% | 0.0% |
| Q2 2023 | $17,493 | -41.5% | 196 | -29.7% | 0.00% | -33.3% |
| Q1 2023 | $29,915 | -30.0% | 279 | -20.3% | 0.00% | -40.0% |
| Q4 2022 | $42,746 | +47.4% | 350 | +25.4% | 0.01% | +25.0% |
| Q3 2022 | $29,000 | +81.2% | 279 | +59.4% | 0.00% | +100.0% |
| Q2 2022 | $16,000 | -33.3% | 175 | -14.6% | 0.00% | -33.3% |
| Q1 2022 | $24,000 | -33.3% | 205 | -22.3% | 0.00% | -25.0% |
| Q4 2021 | $36,000 | +5.9% | 264 | +23.9% | 0.00% | -20.0% |
| Q3 2021 | $34,000 | +47.8% | 213 | +23.8% | 0.01% | +66.7% |
| Q2 2021 | $23,000 | +155.6% | 172 | +145.7% | 0.00% | +200.0% |
| Q1 2021 | $9,000 | +28.6% | 70 | +59.1% | 0.00% | 0.0% |
| Q4 2020 | $7,000 | +75.0% | 44 | +63.0% | 0.00% | 0.0% |
| Q3 2020 | $4,000 | 0.0% | 27 | +3.8% | 0.00% | 0.0% |
| Q2 2020 | $4,000 | – | 26 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |